- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Molly Burich Discusses the Lack of Interchangeable Biosimilars
Molly Burich, MS, head of public policy at Boehringer Ingelheim, discusses the why there currently are no biosimilars with an interchangeability designation during the World Biosimilar Congress USA 2020 at the Festival of Biologics USA in San Diego, California..
Molly Burich, MS, is the head of public policy at Boehringer Ingelheim.
Transcript:
So far, there are no interchangeable biosimilars. Why is that?
The reason why we don't have any interchangeable biosimilars yet is because all that are launched are on the medical benefit side, meaning they're administered by the physician. And without that pharmacy interplay, there's really no need to have an interchangeability designation because that really is the primary goal of that designation, is to allow for that. When a physician is managing their own inventory and managing the switch, there is no pharmacy interaction. So, we haven't seen interchangeable[s] yet because, right now, we don't have any pharmacy benefit—approved biosimilars.
How Vertical Integration Drives Innovation and Access in Biosimilars
December 27th 2024Elie Bahou, PharmD, highlights how vertical integration in the biosimilar industry streamlines costs, improves supply reliability, accelerates market adoption, and enhances patient access, while emphasizing the value of collaboration, quality control, and value-based contracts for sustainable health care delivery.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.
Q&A: Dr Kimberly Maxfield Explains How BsUFA III Will Advance the US Biosimilar Industry
December 20th 2023At AMCP Nexus, Kimberly Maxfield, PhD, pharmacologist at the FDA, delved into how the third reauthorization of the Biosimilar User Fee Act (BsUFA III) will shape the American biosimilar market and improve development efficiency over the next few years.
